FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492752> ?p ?o ?g. }

• W4280492752 endingPage "103619" @default.
• W4280492752 startingPage "103619" @default.
• W4280492752 abstract "Background: Cladribine tablets are approved for relapsing multiple sclerosis (RMS) treatment in many jurisdictions. MSBase investigators are committed to characterizing real-world longitudinal treatment outcomes using this registry data. The objective of this study was to describe cladribine treatment outcomes in the MSBase cohort. These include baseline characteristics, treatment pathways, discontinuation rate, and relapse outcomes.Material(s) and Method(s): We extracted data from the MSBase registry for all patients with a confirmed diagnosis of MS who were newly treated with cladribine tablets. Descriptive statistics were used to analyse baseline patient characteristics recorded within 3 months prior to cladribine tablets initiation, including demographics, disease course and duration, prior disease-modifying therapies (DMT), and Expanded Disability Status Scale (EDSS). Relapse and discontinuation outcomes were described in patients with a minimum 6-month observation period.Result(s): As of 3rd March 2021, a total of 782 patients, predominantly from Australia, Canada and Spain, were included. From those, 696 were relapsing-remitting MS (RRMS) patients. The median age of cladribine tablets start was 43.8 years and median disease duration was 11.8 years. Median EDSS at cladribine initiation was 2 (IQR 1.5,4). Overall, 13.3% of all RRMS patients initiated cladribine tablets as first-line therapy. Of all RRMS patients switching to cladribine tablets with a treatment gap of <6 months, the most common immediate prior DMT was fingolimod (15%), followed by natalizumab (10%) and teriflunomide (9.5%). Total follow-up time was 629 patient-years. Annualized relapse rate (ARR) on cladribine tablets was 0.11 (95% confidence interval [CI]: 0.09-0.14) compared to a 12-month pre-cladribine ARR of 0.41. Treatment persistence was 96% at 12 months (95% CI: 0.94-0.98) and 90% after 24 months (95% CI: 0.85-0.94).Conclusion(s): The growing MSBase real-world cladribine tablets cohort shows excellent outcomes to date. The most common switches to cladribine are from other high-efficacy DMTs such as natalizumab or fingolimod. The annualized relapse rate on treatment is 0.11, consistent with clinical trial data. The observed discontinuation rate over 24 months is very low, at 9%. Background: Cladribine tablets are approved for relapsing multiple sclerosis (RMS) treatment in many jurisdictions. MSBase investigators are committed to characterizing real-world longitudinal treatment outcomes using this registry data. The objective of this study was to describe cladribine treatment outcomes in the MSBase cohort. These include baseline characteristics, treatment pathways, discontinuation rate, and relapse outcomes. Material(s) and Method(s): We extracted data from the MSBase registry for all patients with a confirmed diagnosis of MS who were newly treated with cladribine tablets. Descriptive statistics were used to analyse baseline patient characteristics recorded within 3 months prior to cladribine tablets initiation, including demographics, disease course and duration, prior disease-modifying therapies (DMT), and Expanded Disability Status Scale (EDSS). Relapse and discontinuation outcomes were described in patients with a minimum 6-month observation period. Result(s): As of 3rd March 2021, a total of 782 patients, predominantly from Australia, Canada and Spain, were included. From those, 696 were relapsing-remitting MS (RRMS) patients. The median age of cladribine tablets start was 43.8 years and median disease duration was 11.8 years. Median EDSS at cladribine initiation was 2 (IQR 1.5,4). Overall, 13.3% of all RRMS patients initiated cladribine tablets as first-line therapy. Of all RRMS patients switching to cladribine tablets with a treatment gap of <6 months, the most common immediate prior DMT was fingolimod (15%), followed by natalizumab (10%) and teriflunomide (9.5%). Total follow-up time was 629 patient-years. Annualized relapse rate (ARR) on cladribine tablets was 0.11 (95% confidence interval [CI]: 0.09-0.14) compared to a 12-month pre-cladribine ARR of 0.41. Treatment persistence was 96% at 12 months (95% CI: 0.94-0.98) and 90% after 24 months (95% CI: 0.85-0.94). Conclusion(s): The growing MSBase real-world cladribine tablets cohort shows excellent outcomes to date. The most common switches to cladribine are from other high-efficacy DMTs such as natalizumab or fingolimod. The annualized relapse rate on treatment is 0.11, consistent with clinical trial data. The observed discontinuation rate over 24 months is very low, at 9%." @default.
• W4280492752 created "2022-05-22" @default.
• W4280492752 creator A5005127716 @default.
• W4280492752 creator A5006704248 @default.
• W4280492752 creator A5025814190 @default.
• W4280492752 creator A5026073997 @default.
• W4280492752 creator A5028230236 @default.
• W4280492752 creator A5042431509 @default.
• W4280492752 creator A5058927839 @default.
• W4280492752 creator A5060950347 @default.
• W4280492752 creator A5061850989 @default.
• W4280492752 creator A5081187567 @default.
• W4280492752 date "2022-03-01" @default.
• W4280492752 modified "2023-09-28" @default.
• W4280492752 title "Real-World Experience with Cladribine in the MSBase Registry" @default.
• W4280492752 doi "https://doi.org/10.1016/j.msard.2022.103619" @default.
• W4280492752 hasPublicationYear "2022" @default.
• W4280492752 type Work @default.
• W4280492752 citedByCount "1" @default.
• W4280492752 countsByYear W42804927522023 @default.
• W4280492752 crossrefType "journal-article" @default.
• W4280492752 hasAuthorship W4280492752A5005127716 @default.
• W4280492752 hasAuthorship W4280492752A5006704248 @default.
• W4280492752 hasAuthorship W4280492752A5025814190 @default.
• W4280492752 hasAuthorship W4280492752A5026073997 @default.
• W4280492752 hasAuthorship W4280492752A5028230236 @default.
• W4280492752 hasAuthorship W4280492752A5042431509 @default.
• W4280492752 hasAuthorship W4280492752A5058927839 @default.
• W4280492752 hasAuthorship W4280492752A5060950347 @default.
• W4280492752 hasAuthorship W4280492752A5061850989 @default.
• W4280492752 hasAuthorship W4280492752A5081187567 @default.
• W4280492752 hasBestOaLocation W42804927521 @default.
• W4280492752 hasConcept C126322002 @default.
• W4280492752 hasConcept C187212893 @default.
• W4280492752 hasConcept C203014093 @default.
• W4280492752 hasConcept C2776036978 @default.
• W4280492752 hasConcept C2777703276 @default.
• W4280492752 hasConcept C2778715236 @default.
• W4280492752 hasConcept C2779200787 @default.
• W4280492752 hasConcept C2780640218 @default.
• W4280492752 hasConcept C2780892749 @default.
• W4280492752 hasConcept C2781004633 @default.
• W4280492752 hasConcept C71924100 @default.
• W4280492752 hasConceptScore W4280492752C126322002 @default.
• W4280492752 hasConceptScore W4280492752C187212893 @default.
• W4280492752 hasConceptScore W4280492752C203014093 @default.
• W4280492752 hasConceptScore W4280492752C2776036978 @default.
• W4280492752 hasConceptScore W4280492752C2777703276 @default.
• W4280492752 hasConceptScore W4280492752C2778715236 @default.
• W4280492752 hasConceptScore W4280492752C2779200787 @default.
• W4280492752 hasConceptScore W4280492752C2780640218 @default.
• W4280492752 hasConceptScore W4280492752C2780892749 @default.
• W4280492752 hasConceptScore W4280492752C2781004633 @default.
• W4280492752 hasConceptScore W4280492752C71924100 @default.
• W4280492752 hasLocation W42804927521 @default.
• W4280492752 hasOpenAccess W4280492752 @default.
• W4280492752 hasPrimaryLocation W42804927521 @default.
• W4280492752 hasRelatedWork W2001220614 @default.
• W4280492752 hasRelatedWork W2002450319 @default.
• W4280492752 hasRelatedWork W2883377714 @default.
• W4280492752 hasRelatedWork W2886874806 @default.
• W4280492752 hasRelatedWork W2897587086 @default.
• W4280492752 hasRelatedWork W2959474424 @default.
• W4280492752 hasRelatedWork W3030177861 @default.
• W4280492752 hasRelatedWork W4231995187 @default.
• W4280492752 hasRelatedWork W4315700955 @default.
• W4280492752 hasRelatedWork W2884925524 @default.
• W4280492752 hasVolume "59" @default.
• W4280492752 isParatext "false" @default.
• W4280492752 isRetracted "false" @default.
• W4280492752 workType "article" @default.